Matthew A. Spear's most recent trade in Poseida Therapeutics Inc was a trade of 72,568 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 72,568 | 72,568 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 50,000 | 111,485 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 06 Dec 2021 | 10,000 | 61,485 | - | 1.3 | 13,220 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 10,000 | 70,861 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 09 Sep 2021 | 10,000 | 51,485 | - | 1.3 | 13,220 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2021 | 10,000 | 80,861 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.79 per share. | 20 Aug 2021 | 4,000 | 41,485 | - | 8.8 | 35,142 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 4,000 | 90,861 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 20 Aug 2021 | 4,000 | 45,485 | - | 1.3 | 5,288 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 28 Jul 2021 | 20,000 | 41,485 | - | 1.3 | 26,440 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2021 | 20,000 | 94,861 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 5,000 | 114,861 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 17 Jun 2021 | 5,000 | 21,485 | - | 1.3 | 6,610 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.44 per share. | 11 Jun 2021 | 4,000 | 16,485 | - | 9.4 | 37,747 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2021 | 4,000 | 119,861 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 11 Jun 2021 | 4,000 | 20,485 | - | 1.3 | 5,288 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 164,000 | 164,000 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 15 Jan 2021 | 7,564 | 11,485 | - | 1.3 | 10,000 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 7,564 | 132,861 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 08 Jan 2021 | 3,921 | 3,921 | - | 1.3 | 5,184 | Common Stock |
| Poseida Therapeutics Inc | Matthew A. Spear | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 3,921 | 140,425 | - | - | Stock Option (Right to Buy) |